Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

By A. Haslam, V. Prasad. JAMA Network Open, 2019

1,195 citations recorded by the source corpus.

Key Points Question What is the estimated percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor drugs approved for oncology indications by the US Food and Drug Administration? Findings This cross-sectional study found that the estimated percentage of US patients with cancer who are eligible for checkpoint inhibitor drugs increased from 1.54% in 2011 to 43.63% in 2018. The percentage of patients estimated to respond to checkpoint inhibitor drugs was 0.14% in 2011 and increased to 12.46% in 2018. Meaning The estimated percentages of patients who are eligible for and who respond to checkpoint inhibitor drugs are higher than reported estimates for drugs approved for genome-driven oncology but remain modest.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/122e09ee3bde1a6a27389704f48cf4a7dc859a55

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. I. Gögenur
2. J. Christensen
3. A. Orhan
4. H. Raskov

Citations in the corpus

• Cytotoxic CD8+ T cells in cancer and cancer immunotherapy (2020, background): “However, the overall response rate of 13% in eligible patients is lower than that hoped for and might translate into serious overtreatment with unnecessary risks of severe side effects.(42) The one-shot cures of lymphomas and leukaemias delivered by CAR T-cells in early clinical trials were unexpect”